car t studies with significantly delayed onset of gvhd
Published 1 year ago • 141 plays • Length 1:00Download video MP4
Download video MP3
Similar videos
-
56:58
translatable efficacy & safety testing of mab, bispecific, & car t therapies
-
21:39
jax tech talk #50: let’s talk accelerating development of car t therapies (15feb2022)
-
37:21
car t-cell cytotoxicity of solid tumors is dependent on ifnγr signaling & downstream adhesion
-
27:28
mesothelin-specific car-t cell therapy with hla-gated safety mechanism selectively kills tumor cells
-
7:07
the science of car t cells
-
55:15
efficacy and safety of therapeutics in immuno-modulatory induced cytokine release syndrome
-
1:32
car t cell therapy explained (animation) | city of hope
-
51:02
webinar: in vivo preclinical efficacy & safety of car-t, -nk, and -myeloid based therapies
-
1:33
patient selection for car-t in all
-
34:53
engineered t cell with cars and tcrs for hematologic malignancy
-
44:27
comparing immunodeficient models for cancer, immunity, and transplant research
-
3:26
access to car t-cell therapy
-
48:50
engineering t cells for cancer - carl june
-
16:40
jax tech talk #48: developing immunotherapies with hu-nsg-mhc i/ii dko mice (11jan2022)
-
2:54
centralized and decentralized car t-cell manufacturing
-
57:52
webinar: human immune system engrafted platforms for more translatable preclinical research
-
7:51
managing car t-cell therapy toxicity
-
3:57
mechanisms and management of short- and long-term car-t toxicities
-
3:18
evaluating dual-targeting cd19/22 car-t cells in patients with r/r all